CN109939065B - 医用水凝胶 - Google Patents

医用水凝胶 Download PDF

Info

Publication number
CN109939065B
CN109939065B CN201810909023.2A CN201810909023A CN109939065B CN 109939065 B CN109939065 B CN 109939065B CN 201810909023 A CN201810909023 A CN 201810909023A CN 109939065 B CN109939065 B CN 109939065B
Authority
CN
China
Prior art keywords
aldehyde
polyethylene glycol
solution
arm polyethylene
terminated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810909023.2A
Other languages
English (en)
Other versions
CN109939065A (zh
Inventor
潘震
陈亮
侯森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Ruining Biotechnology Co ltd
Original Assignee
Shanghai Ruining Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Ruining Biotechnology Co ltd filed Critical Shanghai Ruining Biotechnology Co ltd
Priority to CN201810909023.2A priority Critical patent/CN109939065B/zh
Priority to PCT/CN2018/111398 priority patent/WO2020029432A1/zh
Priority to US17/267,788 priority patent/US20210162092A1/en
Publication of CN109939065A publication Critical patent/CN109939065A/zh
Application granted granted Critical
Publication of CN109939065B publication Critical patent/CN109939065B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001Use of materials characterised by their function or physical properties
    • A61L24/0031Hydrogels or hydrocolloids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/043Mixtures of macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/041Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/145Hydrogels or hydrocolloids
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G12/00Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen
    • C08G12/46Block or graft polymers prepared by polycondensation of aldehydes or ketones on to macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/40Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
    • C08G2650/30Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type branched
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02Polyalkylene oxides
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L77/00Compositions of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Compositions of derivatives of such polymers
    • C08L77/04Polyamides derived from alpha-amino carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L79/00Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
    • C08L79/02Polyamines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明公开了一种医用水凝胶,由醛基封端的星形多臂聚乙二醇和多氨基化合物原位交联而成,所述醛基与星形多臂聚乙二醇之间以醚键、酰胺键、氨酯键、亚胺键或脲键化学键连接。本发明利用多臂聚乙二醇端部的醛基和多氨基化合物的氨基反应生成schiff碱从而产生交联,形成医用可注射凝胶。所制得的凝胶成胶时间短,具有理想的凝胶胀破强度,并且在水溶液中稳定性好,相较于现有医用凝胶具有更好的应用价值。

Description

医用水凝胶
技术领域
本发明属于生物医药技术领域,具体涉及一种医用水凝胶,可用于术后组织密封与防渗漏、防组织黏连、组织填充剂、组织修复、皮肤敷料和药物释放等领域。
背景技术
水凝胶是一种由亲水性聚合物交联得到的含有大量水分的软材料。水凝胶具有优良的理化性能和生物学特性,如高含水量、高弹性、柔软、具有生物相容性等特点,在药物转运、组织工程等生物医学研究领域有着重要的应用价值。可注射水凝胶是指具有一定流动性的、能够通过注射的方法应用的一类水凝胶,对于外界刺激(温度,温度/pH等变化)呈现出溶胶与凝胶间的相转变,在注射入人体之前呈液态或是具有剪切变稀性质的半固态,在注射入人体内之后能原位成胶,因而不需要侵入性手术,这有效地避免了感染的风险,并减捏了病人的痛苦。目前已发展的各种可注射的PEG水凝胶包括PEG为亲水段的两亲性聚酯/聚肽水凝胶、超分子作用制备的PEG水凝胶以及通过温和化学反应制备的PEG水凝胶。
聚乙二醇(polyethylene glycol,PEG)是一类非离子型聚合物,由于其本身有较好的生物相容性和安全性,是获美国食品和药品管理局(FDA)许可的可应用在人类临床的一类合成聚合物。PEG既可以作为药用辅料,又可以使用含有末端活泼官能团的PEG对药物进行修饰(聚乙二醇化)。聚乙二醇化技术具有较多的优点,尤其是在修饰蛋白和多肽类药物方面:具有延长其体内循环时间、增强生物活性、避免蛋白水解和降低免疫反应的特点。可通过连接活性末端官能团,如氨基、硫醇基、叠氮、炔基和醛基等制备聚乙二醇偶联物来提高聚乙二醇的性能。
CN105963792A公开了一种医用水凝胶组合物,包括第一组分和第二组分,所述第一组分包括聚赖氨酸和聚乙烯亚胺;所述第二组分包括四臂-聚乙二醇-琥珀酰亚胺戊二酸酯、四臂-聚乙二醇-琥珀酰亚胺丁二酸酯、四臂-聚乙二醇-琥珀酰亚胺碳酸酯中的一种或几种。使用时将第一组分的亲核试剂(聚赖氨酸和聚乙烯亚胺)与第二组分的亲电试剂(四臂-聚乙二醇-琥珀酰亚胺戊二酸酯、四臂-聚乙二醇-琥珀酰亚胺丁二酸酯、四臂-聚乙二醇-琥珀酰亚胺碳酸酯中的一种或几种)发生迈克尔加成反应,可以快速成胶具有低溶胀的优良性质。然而,琥珀酰亚胺有机酸酯封端的聚乙二醇材料在水中半衰期很短,极易水解,需要特别的技术才能以粉末的形式在室温长期保存,且在溶解之后很短时间内(一般为1个小时)使用,便利性较低。
CN107693838A公开了一种医用可注射凝胶及其制备方法,将浓度为2-20%(w/v)醛基封端超支化聚合物HP-PEG-CHO溶液与浓度为2-20%(w/v)多氨基化合物溶液通过双组份注射器混合后喷涂,利用醛基和氨基反应生成西弗碱从而产生交联,形成医用可注射凝胶。醛基封端超支化聚合物HP-PEG-CHO中的醛基以酯键与聚合物连接,在水溶液中的长期稳定性较低,另外超支化聚合物分子量分布较宽,可能含有较高分子量的聚合物,不利于人体排出。
发明内容
本发明针对现有技术不足,提供了一种水溶液可长期稳定保存、基于多臂星形聚乙二醇的医用水凝胶。
本发明具体技术方案如下:
一种医用水凝胶,由醛基封端的星形多臂聚乙二醇和多氨基化合物原位交联而成,所述醛基与星形多臂聚乙二醇之间以醚键、酰胺键、氨酯键、亚胺键或脲键等不易水解键连接。
所述多氨基化合物选自聚乙烯亚胺和聚赖氨酸中的一种或多种。
所述醛基封端的多臂聚乙二醇为臂数不小于2,分子量不小于2000的多臂聚乙二醇。
所述醛基封端的多臂聚乙二醇的臂数为2-8,优选为8。
所述醛基选自芳香醛、烷基醛中的一种或几种,优选为苯醛基。
本发明另一目的在于提供所述医用水凝胶在术后组织密封与防渗漏、防组织黏连、组织填充剂、组织修复、皮肤敷料和药物制剂中的应用。
本发明另一目的在于提供所述医用水凝胶的制备方法,将醛基封端的星形多臂聚乙二醇溶解在pH4-10缓冲液中,配置醛基封端的星形多臂聚乙二醇溶液;将多氨基化合物溶解在pH4-10缓冲液中,配置多氨基化合物溶液;将两者混合得到医用水凝胶。
本发明所用的醛基封端的星形多臂聚乙二醇可以通过商业途径购买。
上述pH4-10缓冲液优选pH4-10的磷酸盐或硼酸盐缓冲液。
所述醛基封端的星形多臂聚乙二醇溶液的终浓度为2-30%(w/v),优选为10-20%(w/v);所述多氨基化合物溶液浓度为0.5-20%,优选为1-5%(w/v)
所述醛基封端的星形多臂聚乙二醇中醛基与多氨基化合物中氨基物质的量比例为0.01-5:1。
本发明在具体应用时先制备成双组份水凝胶,为包含亲核官能团的第一组分和包含亲电官能团的第二组分,所述第一组分为醛基封端的亲水性化合物,其中臂的个数不低于两个,亲水性化合物为醛基封端的星形多臂聚乙二醇,优选为八臂聚乙二醇(分子量5000-20000),醛基为芳香醛、烷基醛中的一种或几种,优选为苯醛基。醛基与聚合物之间可以以醚键、酰胺键等不易水解的化学键连接。
所述第二组分可以选择包含多氨基的化合物,包括聚赖氨酸(包括ε-聚赖氨酸和多聚赖氨酸)和聚乙烯亚胺中的一种或几种的混合组分。
Figure BDA0001761293680000031
酰胺键连接苯醛基封端八臂聚乙二醇、醚键连接苯醛基封端八臂聚乙二醇、醚键连接丙醛基封端八臂聚乙二醇的化学结构如下所示。
Figure BDA0001761293680000041
Figure BDA0001761293680000051
由于醛基和氨基在水溶液中的稳定性,以上两组分均可以以水溶液或粉末形式提供。使用时将两组分分别溶解于缓冲液中,然后混合组分即得到水凝胶。可将水凝胶两组分分别存储在双管注射器中,使用时两个组分经混合头喷出或者注射到指定部位形成凝胶。
本发明利用多臂聚乙二醇端部的醛基和多氨基化合物的氨基反应生成schiff碱从而产生交联,形成医用可注射凝胶。所制得的凝胶成胶时间短,具有理想的凝胶胀破强度,并且在水溶液中稳定性好,相较于现有医用凝胶具有更好的应用价值。
附图说明
图1为醚键连接、酰胺键连接和酯键连接的醛基封端聚乙二醇成胶稳定性考察结果。
具体实施方式
以下通过实施例说明本发明的具体步骤,但不受实施例限制。
在本发明中使用的术语,除非另有说明,一般具有本领域普通技术人员通常理解的含义。
下面结合具体实施例并参照数据进一步详细描述本发明,应理解,这些实施例只是为了举例说明本发明,而非以任何方式限制本发明的范围。
在以下实施例中,未详细描述的各种过程和方法是本领域中公知的常规方法。
下面结合具体实施例对本发明进行进一步描述,但本发明的保护范围并不仅限于此。
实施例1
将600mg的醚键连接苯醛基封端8臂聚乙二醇8-PEG-O-BA(M.W.10K)溶解在2mL的磷酸盐缓冲液中(pH7.4),作为A溶液;配置聚乙烯亚胺2.2%(w/v)的磷酸盐缓冲液溶液,作为B溶液;将A、B溶液等体积混合即获得具有粘性的水凝胶,成胶时间为21秒,凝胶胀破强度为16kPa。
实施例2
将600mg的醚键连接苯醛基封端8臂聚乙二醇8-PEG-O-BA(M.W.13.5K)溶解在2mL的磷酸盐缓冲液中(pH7.4),作为A溶液;配置聚乙烯亚胺1.67%(w/v)的磷酸盐缓冲液溶液,作为B溶液;将A、B溶液等体积混合即获得具有粘性的水凝胶,成胶时间为22秒,凝胶胀破强度为11kPa。
实施例3
将400mg酰胺键连接苯醛基封端8臂聚乙二醇8-PEG-amide-BA(M.W.10K)溶解在2mL的磷酸盐缓冲液中(pH7.4),作为A溶液;配置聚乙烯亚胺1.48%(w/v)的磷酸盐缓冲液溶液,作为B溶液;将A、B溶液等体积混合即获得具有粘性的水凝胶,成胶时间为2秒,凝胶胀破强度为13kPa。
实施例4
将600mg酰胺键连接苯醛基封端4臂聚乙二醇4-PEG-amide-BA(M.W.10K)溶解在2mL的磷酸盐缓冲液中(pH7.4),作为A溶液;配置聚乙烯亚胺2.2%(w/v)的磷酸盐缓冲液溶液,作为B溶液;将A、B溶液等体积混合即获得具有粘性的水凝胶,成胶时间为20秒,凝胶胀破强度为11kPa。
实施例5
将400mg酰胺键连接苯醛基封端8臂聚乙二醇8-PEG-amide-BA(M.W.10K)溶解在2mL的磷酸盐缓冲液中(pH7.4),作为A溶液;配置聚赖氨酸2.44%(w/v)的磷酸盐缓冲液溶液,作为B溶液;将A、B溶液等体积混合即获得具有粘性的水凝胶,成胶时间为5秒,凝胶胀破强度为21kPa。
实施例6
将400mg酰胺键连接苯醛基封端8臂聚乙二醇8-PEG-amide-BA(M.W.10K)溶解在2mL的磷酸盐缓冲液中(pH7.4),作为A溶液;配置聚赖氨酸3.66%(w/v)的磷酸盐缓冲液溶液,作为B溶液;将A、B溶液等体积混合即获得具有粘性的水凝胶,成胶时间为5秒,凝胶胀破强度为25kPa。
实施例7
将600mg的醚键连接丙醛基封端8臂聚乙二醇8-PEG-O-PA(M.W.10K)溶解在2mL的磷酸盐缓冲液中(pH7.4),作为A溶液;配置聚乙烯亚胺1.48%(w/v)的磷酸盐缓冲液溶液,作为B溶液;将A、B溶液等体积混合即获得具有粘性的水凝胶,成胶时间为15秒,凝胶胀破强度8kPa。
实施例8
将600mg的醚键连接苯醛基封端8臂聚乙二醇8-PEG-O-BA(M.W.13.5K)溶解在2mL的磷酸盐缓冲液中(pH7.4),作为A溶液;配置聚赖氨酸2.75%(w/v)的磷酸盐缓冲液溶液,作为B溶液;将A、B溶液等体积混合即获得具有粘性的水凝胶,成胶时间小于5分钟,凝胶胀破强度为2kPa。
实施例9
将600mg的醚键连接苯醛基封端8臂聚乙二醇8-PEG-O-BA(M.W.13.5K)溶解在2mL的磷酸盐缓冲液中(pH7.4),作为A溶液;配置含聚赖氨酸2.75%(w/v)和聚乙烯亚胺(M.W.1.8K)1%(w/v)的磷酸盐缓冲液溶液,作为B溶液;将A、B溶液等体积混合即获得具有粘性的水凝胶,成胶时间35秒,凝胶胀破强度为22kPa。
实施例10
将400mg酯键连接苯醛基封端8臂聚乙二醇8-PEG-amide-BA(M.W.10K)溶解在2mL的磷酸盐缓冲液中(pH7.4),作为A溶液;配置聚乙烯亚胺(M.W.1.8K)1.48%(w/v)的磷酸盐缓冲液溶液,作为B溶液;将A、B溶液等体积混合即获得具有粘性的水凝胶,成胶时间为5秒,凝胶胀破强度为13kPa。
实施例11
比较醚键连接、酰胺键连接和酯键连接的苯醛基封端聚乙二醇在水溶液中的长期稳定性,为了缩短试验时间,选择碱性硼酸盐缓冲液作为溶剂,比较不同时间点成胶时间的变化。分别将400mg的醚键连接、酰胺键连接和酯键连接苯醛基封端8臂聚乙二醇(M.W.10K)溶解在2mL的0.1M硼酸盐缓冲液(pH9.2),作为A溶液;配置含聚乙烯亚胺(M.W.1.8K)1.48%(w/v)的磷酸盐缓冲液溶液,作为B溶液;将A、B溶液等体积混合即获得具有粘性的水凝胶,初始成胶时间分别为25秒、2秒和5秒。将三种A液置于37℃烘箱1、2、4、16、24和40小时,再分别测定与B液混合后的成胶时间与初始成胶时间的变化(如图1所示)。结果显示,酯键连接的聚乙二醇在40小时后失去成胶能力,而醚键连接和酰胺键连接苯醛基封端8臂聚乙二醇成胶时间基本保持不变。

Claims (6)

1.一种医用水凝胶,其特征在于由醛基封端的星形多臂聚乙二醇和多氨基化合物原位交联 而成,所述醛基与星形多臂聚乙二醇之间以醚键或酰胺键连接,所述多氨基化合物选自聚乙烯亚胺和聚赖氨酸中的一种或多种,所述醛基封端的星形多臂聚乙二醇为臂数为2-8,分子量不小于2000的多臂聚乙二醇,所述醛基选自芳香醛、烷基醛中的一种或几种。
2.根据权利要求1所述医用水凝胶在制备术后组织密封、防渗漏、防组织黏连、组织填充、组织修复、皮肤敷料的材料或药物制剂中的应用。
3.根据权利要求1所述医用水凝胶的制备方法,其特征在于将醛基封端的星形多臂聚乙二醇溶解在 pH4-10 缓冲液中,配置醛基封端的星形多臂聚乙二醇溶液;将多氨基化合物溶解在 pH4-10 缓冲液中,配置多氨基化合物溶液;将两者混合得到医用水凝胶。
4.根据权利要求3所述医用可注射凝胶制备方法,其特征在于所述醛基封端的星形多臂聚乙二醇溶液的终浓度为 2-30 %,所述多氨基化合物溶液浓度为0.5-20% 。
5.根据权利要求3所述医用可注射凝胶制备方法,其特征在于所述醛基封端多臂的星形聚乙二醇溶液的终浓度为10 ~ 20%,所述多氨基化合物溶液浓度为1-5% 。
6.根据权利要求3所述医用可注射凝胶制备方法,其特征在于所述醛基封端的星形多臂聚乙二醇中醛基与多氨基化合物中氨基物质的量比例为0.01- 5:1。
CN201810909023.2A 2018-08-10 2018-08-10 医用水凝胶 Active CN109939065B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201810909023.2A CN109939065B (zh) 2018-08-10 2018-08-10 医用水凝胶
PCT/CN2018/111398 WO2020029432A1 (zh) 2018-08-10 2018-10-23 医用水凝胶
US17/267,788 US20210162092A1 (en) 2018-08-10 2018-10-23 Medical hydrogel

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810909023.2A CN109939065B (zh) 2018-08-10 2018-08-10 医用水凝胶

Publications (2)

Publication Number Publication Date
CN109939065A CN109939065A (zh) 2019-06-28
CN109939065B true CN109939065B (zh) 2021-08-03

Family

ID=67006324

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810909023.2A Active CN109939065B (zh) 2018-08-10 2018-08-10 医用水凝胶

Country Status (3)

Country Link
US (1) US20210162092A1 (zh)
CN (1) CN109939065B (zh)
WO (1) WO2020029432A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4100072A1 (en) * 2020-02-04 2022-12-14 Boston Scientific Scimed Inc. Injectable in vivo crosslinking materials for use as soft tissue fillers
CN111440310B (zh) * 2020-05-26 2022-02-22 中国科学院长春应用化学研究所 一种聚乙二醇衍生物、其制备方法及可快速发生交联反应的聚乙二醇水凝胶
CN112225912B (zh) * 2020-10-19 2022-11-29 上海瑞凝生物科技有限公司 可降解医用水凝胶
CN114907580A (zh) * 2021-02-09 2022-08-16 上海瓴就医疗科技有限公司 一种可降解的双组份水凝胶及其制备方法与应用
CN113171463B (zh) * 2021-03-31 2022-09-02 北京诺康达医药科技股份有限公司 原位载药水凝胶及其制备方法与应用
CN113461973B (zh) * 2021-07-21 2023-04-07 上海瑞凝生物科技有限公司 可注射型医用水凝胶
CN114369354B (zh) * 2021-08-05 2024-06-18 上海瑞凝生物科技有限公司 用于血管栓塞的可注射水凝胶
CN115869456A (zh) * 2021-08-09 2023-03-31 上海其胜生物制剂有限公司 一种原位凝胶化抗溶胀增强型组织粘合剂材料的制备
CN114767625A (zh) * 2022-05-19 2022-07-22 四川大学 具有心脏损伤修复功能的智能水凝胶及其制备方法和应用
CN115025281A (zh) * 2022-07-15 2022-09-09 上海交通大学 糖基化聚赖氨酸-聚乙二醇水凝胶及其制备方法和应用
CN115353641A (zh) * 2022-07-28 2022-11-18 山东大学 一种人血清白蛋白/聚乙二醇水凝胶及其制备方法与应用
CN115120591B (zh) * 2022-08-03 2024-08-13 上海瑞凝生物科技有限公司 一种peg化喜树碱长效缓释凝胶
CN115068413B (zh) * 2022-08-04 2024-02-23 上海瑞凝生物科技有限公司 一种盐酸阿霉素/盐酸表阿霉素缓释凝胶
CN116077744A (zh) * 2022-08-05 2023-05-09 清华大学 一种可吸收自显影水凝胶及其制备方法、应用
CN116983466A (zh) * 2023-08-16 2023-11-03 南方科技大学 一种医用凝胶敷料及其制备方法和应用
CN118420916B (zh) * 2024-07-03 2024-10-18 浙江巴泰医疗科技有限公司 一种预成型封血塞及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020064546A1 (en) * 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
KR100452972B1 (ko) * 2000-05-16 2004-10-14 주식회사 삼양사 경피투여용 하이드로젤 조성물
WO2009102952A2 (en) * 2008-02-13 2009-08-20 Hyperbranch Medical Technology, Inc. Crosslinked polyalkyleneimine hydrogels with tunable degradation rates
CN103755949B (zh) * 2009-12-25 2016-04-13 天津键凯科技有限公司 多臂聚乙二醇衍生物及其与药物的结合物和凝胶
US8617519B2 (en) * 2011-07-07 2013-12-31 DePuy Synthes Products, LLC Injectable cross-linked hydrogels for biomaterial applications
CN102604011A (zh) * 2012-02-28 2012-07-25 中国科学院化学研究所 一种两亲性多臂星型聚合物及其制备方法
JP6265497B2 (ja) * 2012-09-18 2018-01-24 日産化学工業株式会社 ヒドロゲル形成性組成物及びそれより作られるヒドロゲル
CN105561404B (zh) * 2015-01-07 2019-07-26 北京赛奇科科技有限公司 一种用于妇产科防粘连的医用材料及其制备方法
CN107693838A (zh) * 2017-11-09 2018-02-16 杭州亚慧生物科技有限公司 一种医用可注射凝胶及其制备方法

Also Published As

Publication number Publication date
US20210162092A1 (en) 2021-06-03
CN109939065A (zh) 2019-06-28
WO2020029432A1 (zh) 2020-02-13

Similar Documents

Publication Publication Date Title
CN109939065B (zh) 医用水凝胶
CN109646723B (zh) 具有辐射防护作用的医用水凝胶
CN112225912B (zh) 可降解医用水凝胶
US10322170B2 (en) Hemostatic compositions
US9433699B2 (en) Hydrogel comprising catechol group-coupled chitosan or polyamine and poloxamer comprising thiol group coupled to end thereof, preparation method thereof, and hemostat using same
JP5053758B2 (ja) 急速ゲル化生体適合性ポリマー組成物
JP6017646B2 (ja) 医療用ヒドロゲル組織接着剤
EP3406270B1 (en) Surgical sealant
TW200824726A (en) Rapidly acting dry sealant and methods for use and manufacture
US20160243275A1 (en) Polymer hydrogel adhesives formed with multiple crosslinking mechanisms at physiologic ph
EP2214731A2 (en) Oxidized cationic polysaccharide-based polymer tissue adhesive for medical use
Ghosh et al. Strong poly (ethylene oxide) based gel adhesives via oxime cross-linking
JP2012523289A (ja) 減少した分解時間を有するハイドロゲル組織接着剤
Otani et al. Effect of additives on gelation and tissue adhesion of gelatin–poly (L-glutamic acid) mixture
JP2010520799A (ja) 組織癒着防止のためのシステム、方法、および組成物
CN114369354B (zh) 用于血管栓塞的可注射水凝胶
KR20110076826A (ko) 수화겔, 이의 제조 방법 및 용도
US8440309B2 (en) Crosslinked polymers with the crosslinker as therapeutic for sustained release
CN113461973B (zh) 可注射型医用水凝胶
CN115725088A (zh) 透明质酸-聚乙二醇医用水凝胶
Modak et al. Dynamic, 3D Schiff base networks for medical applications
EP2877514A1 (en) Heat-sensitive amphiphilic polyurethane and aqueous solution capable of being injected based on such material
Keshari et al. In Situ Gelling Tissue Adhesive Hydrogels for Wound Closure and Tissue Regeneration
CN117736565A (zh) 一种可快速降解的聚乙二醇水凝胶及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant